148 related articles for article (PubMed ID: 11201000)
1. [Recommendations by the Pediatric and Adolescent Rheumatology Study Committee on therapy with Etanercept (p75 TNF-alpha receptor immunoglobulin fusion protein. Pharmacotherapy Committee].
Horneff G; Forster J; Seyberth HW; Michels H;
Z Rheumatol; 2000 Dec; 59(6):365-9. PubMed ID: 11201000
[No Abstract] [Full Text] [Related]
2. Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis.
Lepore L; Marchetti F; Facchini S; Leone V; Ventura A
Clin Exp Rheumatol; 2003; 21(2):276-7. PubMed ID: 12747299
[No Abstract] [Full Text] [Related]
3. Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis.
Kuemmerle-Deschner JB; Horneff G
Rheumatol Int; 2007 Dec; 28(2):153-6. PubMed ID: 17641897
[TBL] [Abstract][Full Text] [Related]
4. Granulomatous disease in a child treated with etanercept.
Alhajri M; Aljumaah S; Aleyouni Y; Al-Qahtani F; Alhazzaa S; Al-Mayouf SM
Int J Rheum Dis; 2013 Aug; 16(4):472-4. PubMed ID: 23826822
[No Abstract] [Full Text] [Related]
5. Crohn's disease in a patient with juvenile idiopathic arthritis after starting etanercept therapy - causal link or only temporal coincidence?
Flemming GM; Tóth G; Gebauer C; Schuster V
Klin Padiatr; 2013 Nov; 225(6):350-1. PubMed ID: 24166091
[No Abstract] [Full Text] [Related]
6. Etanercept in four children with therapy-resistant systemic juvenile idiopathic arthritis.
ten Cate R; van Suijlekom-Smit LW; Brinkman DM; Bekkering WP; Jansen-van Wijngaarden CJ; Vossen JM
Rheumatology (Oxford); 2002 Feb; 41(2):228-9. PubMed ID: 11886975
[No Abstract] [Full Text] [Related]
7. Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis.
Nerome Y; Imanaka H; Nonaka Y; Takei S
Mod Rheumatol; 2007; 17(6):526-8. PubMed ID: 18084710
[TBL] [Abstract][Full Text] [Related]
8. Radiologic Improvement of juvenile idiopathic arthritis-enthesitis-related arthritis following anti-tumor necrosis factor-alpha blockade with etanercept.
Tse SM; Laxer RM; Babyn PS; Doria AS
J Rheumatol; 2006 Jun; 33(6):1186-8. PubMed ID: 16755667
[TBL] [Abstract][Full Text] [Related]
9. Etanercept improves active polyarticular juvenile rheumatoid arthritis.
Martini A
Clin Exp Rheumatol; 2001; 19(2):122-4. PubMed ID: 11326472
[No Abstract] [Full Text] [Related]
10. [Application of etanercept in treatment of juvenile idiopathic arthritis and adult onset still disease].
Lewicki M; Kotulska A; Kucharz EJ
Pol Arch Med Wewn; 2005 May; 113(5):505-8. PubMed ID: 16479836
[No Abstract] [Full Text] [Related]
11. Anti-tumour necrosis factor therapy associated with cutaneous vasculitis.
Livermore PA; Murray KJ
Rheumatology (Oxford); 2002 Dec; 41(12):1450-2. PubMed ID: 12468829
[No Abstract] [Full Text] [Related]
12. Response to etanercept in juvenile idiopathic arthritis.
Pang H; Wu XH; Xu JZ
JAMA; 2012 Mar; 307(11):1140; author reply 1140-1. PubMed ID: 22436950
[No Abstract] [Full Text] [Related]
13. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept.
Cummins C; Connock M; Fry-Smith A; Burls A
Health Technol Assess; 2002; 6(17):1-43. PubMed ID: 12234456
[No Abstract] [Full Text] [Related]
14. Etanercept treatment in juvenile idiopathic arthritis: the Polish registry.
Zuber Z; Rutkowska-Sak L; Postępski J; Dobrzyniecka B; Opoka-Winiarska V; Kobusińska K; Gietka P; Osińska V; Turowska-Heydel D; Szczygielska I; Kołodziejczyk B; Świątek-Baczkowska A; Gazda A; Wiland P; Tłustochowicz W; Tuszkiewicz-Misztal E
Med Sci Monit; 2011 Dec; 17(12):SR35-42. PubMed ID: 22129916
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889
[TBL] [Abstract][Full Text] [Related]
16. Etanercept in methotrexate-resistant JIA-related uveitis.
Saeed MU; Raza SH; Goyal S; Cleary G; Newman WD; Chandna A
Semin Ophthalmol; 2014 Jan; 29(1):1-3. PubMed ID: 24175644
[TBL] [Abstract][Full Text] [Related]
17. Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials.
Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Kurosawa R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
Mod Rheumatol; 2011 Dec; 21(6):572-8. PubMed ID: 21479889
[TBL] [Abstract][Full Text] [Related]
18. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
Culy CR; Keating GM
Drugs; 2002; 62(17):2493-537. PubMed ID: 12421111
[TBL] [Abstract][Full Text] [Related]
19. Etanercept in systemic juvenile idiopathic arthritis.
Russo RA; Katsicas MM; Zelazko M
Clin Exp Rheumatol; 2002; 20(5):723-6. PubMed ID: 12412209
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A
Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
